Infectious diseases are one of the leading causes of morbidity and mortality throughout the world. The global market for all infectious diseases is expected to be ~$100 billion dollars by 2022, and is …
MABT’s current mission is to develop therapies for Rabies and advanced Flu patients.
MABT was founded in 2011 with the mission of eradicating life-threatening infectious diseases using a transformative, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.
We are a pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively creating a revolutionary treatment paradigm for viral diseases, such as Rabies and advanced Flu.
Rabies represents a unique unmet medical need, for which there is no effective therapy. Rabies is the most lethal organism known to the medical community, with a fatality rate of essentially 100%. In addition, rabies consistently impacts more lives annually than other viruses that are in the news, like Ebola. For example, in the 40-year history of known Ebola infections ~15,000 people have died but, in that same 40-year period, over 3 million people have died from rabies
IMT504 Super Charges your own Immune System
Rabies represents a unique unmet medical need, for which there is no effective therapy. Rabies is the most lethal organism known to the medical community, with a fatality rate of …
Outside the US, over 700,000 deaths are currently attributed to resistant bacteria. However, given recent trends in resistance, these numbers are expected to skyrocket to over 10,000,000 deaths/year by 2050, …